Yahoo Finance lists HKD 17.66 target: China Medical System stock sits 69.22 percent below it
Published on 10/15/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSValuation and trading levels
- On October 6, 2026, Yahoo Finance listed a one-year target of HKD 17.66.
- China Medical System carried a price-to-earnings ratio of 14.33 on October 15, 2026.
- China Medical System stock costs EUR 1.17 at Lang & Schwarz on October 15, 2026 at 9:46 p.m. CEST, unchanged versus the Xetra close of October 15, 2026.
- Market capitalization was HKD 25.4 billion on October 15, 2026.
China Medical System (KYG211081248) is trading against a wide analyst valuation gap: Yahoo Finance listed a one-year target of HKD 17.66 on October 6, 2026. Against the HKD 10.43 home-market price on October 15, 2026, that target is 69.22 percent higher. At Lang & Schwarz on October 15, 2026 at 9:46 p.m. CEST, China Medical System stock was trading at EUR 1.17, unchanged versus the Xetra close of October 15, 2026.
Target gap remains the key valuation figure
The target is the clearest external valuation marker for the Hong Kong-listed pharmaceutical group. The comparison uses the current HKD 10.43 share price and the HKD 17.66 target in the same currency, producing a 69.22 percent distance.
The operating backdrop is broad rather than concentrated in one product. China Medical System develops, manufactures, markets and distributes pharmaceuticals across cardiovascular, gastroenterology, dermatology and other specialty areas.
Stock sits in the lower range
The home-market quote was HKD 10.43 on October 15, 2026 at 4:08 p.m. HKT. The same-day range was HKD 9.51 to HKD 15.52 over the latest 52-week period, placing the price 30.18 percent above the low and 32.80 percent below the high.
The Hong Kong listing carried a price-to-earnings ratio of 14.33 and a market capitalization of HKD 25.4 billion on October 15, 2026. A separate market profile put the company in the healthcare and specialty pharmaceutical industries and identified 6,415 full-time employees.
Comparison with peers
CMS: unchanged, P/E 14.33, market capitalization HKD 25.4 billion.
CSPC Pharmaceutical Group (HKEX, HKD): plus 0.62 percent, P/E 11.63, market capitalization HKD 101.1 billion.
Sino Biopharmaceutical (HKEX, HKD): plus 2.03 percent, P/E 33.97, market capitalization HKD 93.9 billion.
Trading levels and valuation
The comparison shows a broad spread in market valuation across Hong Kong pharmaceutical companies. CMS trades at a higher earnings multiple than CSPC Pharmaceutical Group but below Sino Biopharmaceutical, while its market value is smaller than both peers.
The next scheduled reporting date was not stated in the dated market material used for this report. The latest reported interim period ended June 30, 2026, according to Simply Wall St.
What the valuation leaves open
For investors, the important contrast is between a HKD 17.66 target and a HKD 10.43 market price, alongside a 14.33 price-to-earnings ratio. The stock also remains materially below its 52-week high, keeping valuation and execution closely linked.
The further course of trading is shown by the continuously updated real-time quote of China Medical System stock.
China Medical System market data
- Company: China Medical System Holdings Limited
- ISIN: KYG211081248
- Ticker: 0867.HK
- Primary exchange: HKEX
- Price Lang & Schwarz (as of October 15, 2026, 9:46 p.m. CEST): EUR 1.17
- Change versus Xetra close: unchanged
- Xetra close (October 15, 2026): EUR 1.17
- Market capitalization: HKD 25.4 billion (as of October 15, 2026)
- 52-week range: HKD 9.51-HKD 15.52 (as of October 15, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Current market reports.
